GlobeNewsWire
27 May 2026, 01:18 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/27/3301588/0/en/Junshi-Biosciences-Announces-Primary-Endpoints-Met-in-Final-Analysis-of-Phase-3-Study-for-Perioperative-Toripalimab-plus-Chemotherapy-for-Resectable-Stage-II-III-NSCLC.html
Read source
Story key points
2 claims · impact-rated
Junshi Biosciences' Phase 3 NEOTORCH study for toripalimab plus chemotherapy met all primary endpoints for resectable stage II-III non-small cell lung cancer (NSCLC). — Positive Phase 3 results are a primary catalyst for biotech valuations and increase the probability of regulatory approval for a high-prevalence disease.
+0.80The company plans to submit a supplemental new drug application (sNDA) to expand toripalimab's approval from stage III to stage II-III NSCLC. — Expanding the indicated patient population directly increases the addressable market and potential revenue streams for the drug.
+0.60Impact vectors
7 dimensions · 9 clusters
Search tags
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company announced that its Phase 3 study for toripalimab met primary endpoints and plans to submit a supplemental new drug application to expand its approved use.
The company announced that its Phase 3 study for toripalimab met primary endpoints and plans to submit a supplemental new drug application to expand its approved use.
No ticker relationship head found.
